Systemic lupus erythematosus (SLE) is a chronic inflammatory connective tissue disease mediated by autoimmunity,[1] affecting mostly young and middle-aged (mean age is 33 years) people.[2] As a dual inhibitor of B-lymphocyte stimulator (BLyS) and A proliferation-inducing ligand (APRIL), telitacicept is commonly prescribed as a weekly 160 mg subcutaneous injection. Additionally, we observed lower levels of immunoglobulin (Ig) G, IgM and IgA compared to baselines, similar to previous studies,[1] indicating that a low dose of telitacicept might also inhibit the abnormal activity of B lymphocytes. Here, using the case of a 56-year-old female patient with long-term SLE and lupus nephritis (LN) who had been diagnosed with herpes zoster within 1 year, we explored the possibility of routine telitacicept use in elderly immunocompromised patients. [Extracted from the article]